“Patients need to understand that even if you tell them that you may be doing this as an ambulatory procedure, they may actually have to stay afterwards, depending on what you find in the operating room or what happens in the postoperative period,” says Michael A. Palese, MD.
Doctors present the patient profile of a 66-year-old man with high-risk localized prostate cancer.
Michael Gorin, MD, describes his experiences with prostate cancer imaging both in academia and community-based practices.
“We saw that this appears to be a safe treatment with very little bleeding,” says Jonathan D. Harper, MD.
“I think the take-home point here is that patient-centered care in the form of navigators to help support patients and provide those frequent check ins really appears to help improve adherence to therapy and progression to advanced therapies,” says Ekene Enemchukwu, MD, MPH.
"Throughout the years, I've said it's not hard to destroy tissue; it's hard to destroy tissue without destroying other things around [the cancer]," says J. Stephen Jones, MD, FACS.
"Cryotherapy was the first energy source that we were able to ablate tissues with in either the kidney or prostate and understand what that ablation would do," says J. Stephen Jones, MD, FACS.
Robert Dreicer, MD, discusses the intensification of androgen-deprivation therapy with androgen receptor pathway inhibitors in patients with metastatic castration-sensitive prostate cancer.
“We want and need consistent buy-in and collaboration with those urologists who are mid and late career. I think that's a good start for anyone [who] wants to get involved,” says Randy Vince Jr, MD.
“Of those patients that did the test phase 82% of them actually went on to full implants,” says Sarah Martin, DO.
“We would have monthly multidisciplinary meetings to pick each other’s brains for tips we can use to get patients home more safely and quickly after surgery,” says Lee.
“The biggest improvement in my patients has been the urgency frequency and urgency incontinence,” says David W. Law, DO.
“I think urology is inherently gendered,” says Polina X. Reyblat, MD.
“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.
An explanation of the importance of clinical providers following a multidisciplinary approach for prostate cancer management.
Experts review ongoing clinical trials in PSMA PET technology.
“It's just very exciting to be a part of a company that's made such an improvement in patients' lives,” says David W. Law, DO.
“We are the only specialty that has an in-depth understanding of the pelvic floor anatomy and physiology of both genders,” says Polina X. Reyblat, MD.
“I think we need really bold and decisive acts to make the type of progress that's needed,” says Randy Vince Jr, MD.
“I think the main thing is placement of the neural probe on the first go around,” says David W. Law, DO.
"We as urologists are board certified to take care of all genders. We are really good sexual medicine doctors, and we need to apply what we know about sexual medicine, not just for our male patients, but for all of our patients," says Rachel S. Rubin, MD
“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.
“There are not enough male reproductive health specialists across the country at the present moment,” says Akanksha Mehta, MD, MS.
“Knowing these disparities exist, I think it's time to demand transformative changes, and not these small transactional initiatives that sometimes seem designed to shut people up,” says Randy Vince Jr, MD.
“One of the most exciting areas of research in sexual health are new improvements on penile implants,” says Marta Skrodzka, MD.
Welcome to another installment of Uranimals, a video series featuring urologists and their pets. From an acrobatic cat to an enemy of landscaping, let’s see who some of the top medical professionals are spending time with when they’re not in the clinic!
“I would suggest a discussion with your medical oncology colleagues, just so that you and your staff know what to expect in the short term and the long term,” says Susan F. Slovin, MD, PhD.
“We really felt that this was an important question to ask because we know that OAB therapy adherence is associated with improvements in urinary symptoms, quality of life, and decreased OAB-related health care costs,” says Ekene Enemchukwu, MD, MPH.
The panel explains the science behind PSMA PET scans and reviews the different positron-emitters used in the scans.
A background on the available options and recent advances in prostate cancer imaging.
